Propanc Biopharma, Inc. (PPCBD) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-02-25.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-02-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-12 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-02-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-01-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-01-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
